logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Mirikizumab for the treatment of moderately to severely active ulcerative colitis

< Back

Mirikizumab for the treatment of moderately to severely active ulcerative colitis

Drugs

Gastrointestinal, Pancreatic and Liver Disease, Renal Disease and Urology

June 2021


Mirikizumab is in clinical development for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). UC is a long-term condition where the colon and rectum (parts of the bowel), become inflamed. Small ulcers can develop on the colon’s lining, which can cause rectal bleeding and recurring diarrhoea. The symptoms of ulcerative colitis often follow a pattern where individuals with the condition have periods of no symptoms or mild symptoms (remission) followed by periods where their symptoms are particularly troublesome (flare-ups or relapses). Additional therapies are required as some therapies do no induce remission in some patients.
Mirikizumab, which is administered intravenously (IV), is a new type of antibody that binds to an inflammatory protein called interleukin 23, inhibiting its activity which prevents the triggering of inflammation. Therefore, if licensed, mirikizumab would offer an additional treatment option for patients with moderately to severely active UC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts